Tags » Dyslipidemia

Dr. Ahmed Hussain

Joint Program Family & Community Medicine, Jeddah – 2014

Background: Due to the tragic raises in the prevalence of both obesity and type 2 diabetes mellitus in Saudi Arabia, which are associated to changes in style of living associated with modernization and socioeconomic growth , adverse changes in the level of blood lipids are not unexpected. 377 more words



NDA Filing Japan, Phase 2 in EU, US

A PPAR-α agonist potentially for the treatment of dyslipidemia.

K-877, K-13675, (R)-

CAS No. 848259-27-8,

Molecular Formula,C28-H30-N2-O6,Molecular Weight,490.553… 1,310 more words

Phase2 Drugs

Allas al qhtani

Prince Sultan Medical Military City, Riyadh – 2014/2015

Dr. Khalid Al Gelban

National Guard Program    – Riyadh  2001/2002

The objective of the present work is to assess the ability of primary care physicians to apply correctly the recent hyperlipidemia management guidelines. 214 more words

Dr. Sharefa Al Anizi

National Guard Program    – Riyadh  2001/2002

Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

(EMAILWIRE.COM, August 11, 2015 ) GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). 24 more words

Dyslipidemia Drugs Market - Global Industry Analysis and Forecast 2015 - 2023

Global Dyslipidemia Drugs Market was valued at USD 17.9 billion in 2014 and is estimated to reach a market worth of USD 6.9 billion in 2023 growing at a CAGR of -10.3% from 2015 to 2023

Press Release